Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia

Othman, Noordin; Vitry, Agnes I.; Roughead, Elizabeth E.; Ismail, Shaiful B.; Omar, Khairani
January 2010
BMC Public Health;2010, Vol. 10, p743
Academic Journal
Background: Pharmaceutical representatives provide medicines information on their promoted products to doctors. However, studies have shown that the quality of this information is often low. No study has assessed the medicines information provided by pharmaceutical representatives to doctors in Malaysia and no recent evidence in Australia is present. We aimed to compare the provision of medicines information by pharmaceutical representatives to doctors in Australia and Malaysia. Methods: Following a pharmaceutical representative's visit, general practitioners in Australia and Malaysia who had agreed to participate, were asked to fill out a questionnaire on the main product and claims discussed during the encounter. The questionnaire focused on provision of product information including indications, adverse effects, precautions, contraindications and the provision of information on the Pharmaceutical Benefit Scheme (PBS) listings and restrictions (in Australia only). Descriptive statistics were produced. Chi-square analysis and clustered linear regression were used to assess differences in Australia and Malaysia. Results: Significantly more approved product information sheets were provided in Malaysia (78%) than in Australia (53%) (P < 0.001). In both countries, general practitioners reported that indications (Australia, 90%, Malaysia, 93%) and dosages (Australia, 76%, Malaysia, 82%) were frequently provided by pharmaceutical representatives. Contraindications, precautions, drug interactions and adverse effects were often omitted in the presentations (range 25% - 41%). General practitioners in Australia and Malaysia indicated that in more than 90% of presentations, pharmaceutical representatives partly or fully answered their questions on contraindications, precautions, drug interactions and adverse effects. More general practitioners in Malaysia (85%) than in Australia (60%) reported that pharmaceutical representatives should have mentioned contraindications, precautions for use, drug interaction or adverse effects spontaneously (P < 0.001). In 48% of the Australian presentations, general practitioners reported the pharmaceutical representatives failed to mention information on PBS listings to general practitioners. Conclusions: Information on indications and dosages were usually provided by pharmaceutical representatives in Australia and Malaysia. However, risk and harmful effects of medicines were often missing in their presentations. Effective control of medicines information provided by pharmaceutical representatives is needed.


Related Articles

  • No agreement on serious drug interactions, study finds. Ukens, Carol // Drug Topics;7/12/2004, Vol. 148 Issue 13, p30 

    This article discusses the findings of a study in the U.S. concerning the alert system for drug-drug interactions (DDI) with greatest clinical importance. According to the study, there is very little agreement on which DDI pose the most risk for patients. The researchers noted that out of 406 of...

  • Cardiac safety of sunitinib questioned.  // Reactions Weekly;1/5/2008, Issue 1183, p1 

    This article reports on the suspicion by U.S.-based researchers that sunitinib may be associated with clinically relevant cardiotoxicity. The researchers are recommending that sunitinib recipients be closely monitored for hypertension and reduction of left ventricular ejection fraction. The...

  • An Automated Standardized System for Managing Adverse Events in Clinical Research Networks. Richesson, Rachel L.; Malloy, Jamie F.; Paulus, Kathleen; Cuthbertson, David; Krischer, Jeffrey P. // Drug Safety;2008, Vol. 31 Issue 10, p807 

    Multi-site clinical protocols and clinical research networks require tools to manage and monitor adverse events (AEs). To be successful, these tools must be designed to comply with applicable regulatory requirements, reflect current data standards, international directives and advances in...

  • Building the process-drug--side effect network to discover the relationship between biological Processes and side effects. Sejoon Lee; Kwang H. Lee; Min Song; Doheon Lee // BMC Bioinformatics;2011 Supplement 2, Vol. 12 Issue Suppl 2, p1 

    Background: Side effects are unwanted responses to drug treatment and are important resources for human phenotype information. The recent development of a database on side effects, the side effect resource (SIDER), is a first step in documenting the relationship between drugs and their side...

  • Adequacy of Patient Information on Adverse Effects: An Assessment of Patient Information Leaflets in the UK. Carrigan, Neil; Raynor, D. K.; Knapp, Peter // Drug Safety;2008, Vol. 31 Issue 4, p305 

    Background: One of the most important categories of information that patients want to know about the drug they are taking is the likelihood or probability of adverse effects. All patients should receive such information in the patient information leaflet that is supplied with all drugs....

  • Health Canada's investment in new post-market drug surveillance network a "pittance". Silversides, Ann // CMAJ: Canadian Medical Association Journal;8/26/2008, Vol. 179 Issue 5, p412 

    The article focuses on the $1 million investment by Health Canada in an independent research network that will study the safety and effects of prescription drugs taken by Canadians. In June 2008, the Parliament's Standing Committee on Health called on the government to form the network that...

  • Thrombolytic administration in the management of subarachnoid hemorrhage. Rice, Ted L.; Middleton, Sarah C.; Laughlin, Karen K. // American Journal of Health-System Pharmacy;9/15/2003, Vol. 60 Issue 18, p1883 

    Papers in the Grand Rounds section are patient case reports and literature review combined in a way that gives them high educational value. The papers lead off with a well-documented case report of an unusual drug experience (e.g., adverse drug reaction, some other unexpected drug response,...

  • Perioperative tenoxicam well tolerated.  // Reactions Weekly;11/6/2004, Issue 1026, p5 

    Discusses research being done on the clinical tolerability of perioperative tenoxicam. Reference to a study by A. F. Merry, C. S. Webster, R. L. Holland, N. G. Middleton, S. A. Schug et al., in the October 2004 issue of "Pain"; Identification of adverse events associated with perioperative...

  • Things to know about adverse reactions to medicine.  // American Family Physician;11/1/1997, Vol. 56 Issue 7, p1791 

    Provides a general overview on adverse drug reactions. Cause of adverse reactions; Suggestions before taking medicines; Adverse drug reactions that people and doctor might notice after taking the medicine; Management of patient with adverse drug reactions.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics